Multiple MBS item numbers may be covered by this panel - briefly:
MBS 73439: patient with a new diagnosis of non-small cell lung cancer
Fee: $682.35 Benefit: 75% = $511.80 85% = $580.00
MBS 73376: patient with clinical or laboratory evidence, including morphological features, of sarcoma - at least 4 genes
Fee: $340.00 Benefit: 75% = $255.00 85% = $289.00
MBS 73380: MAML2 gene rearrangement in mucoepidermoid carcinoma
Fee: $340.00 Benefit: 75% = $255.00 85% = $289.00
MBS 73382: EWSR1 gene rearrangement, with or without PLAG1 gene rearrangement. of hyalinising clear cell carcinoma of the salivary gland
Fee: $340.00 Benefit: 75% = $255.00 85% = $289.00
MBS 73433: neurotrophic receptor tyrosine kinase (NTRK1, NTRK2, NTRK3) fusions by RNA or DNA in tumour tissue from a patient with locally advanced or metastatic solid tumour
Fee: $1,000.00 Benefit: 75% = $750.00 85% = $895.50
MBS 73383 TFE3 gene rearrangement and/or TFEB gene rearrangement in renal cell carcinoma
Fee: $400.00 Benefit: 75% = $300.00 85% = $340.00
MBS 73445 patient presenting with a clinically suspected haematological malignancy of myeloid origin
Fee: $1,100.00 Benefit: 75% = $825.00 85% = $995.50
MBS 73446: as per MBS 73445 if GM NGS Pan-Haem panel also performed
Fee: $1,100.00 Benefit: 75% = $825.00 85% = $995.50 |